Welcome to the REPLACE study
Clinical data indicate that 20–60% of patients with receiving do not reach or maintain treatment goals. Switching to riociguat may be a treatment option for these patients. The REPLACE study investigated the efficacy and safety of switching from to riociguat compared with remaining on in patients with at intermediate risk.
REPLACE key results
The REPLACE study met its primary endpoint. Switching from to riociguat resulted in a significantly higher proportion of patients experiencing clinical improvement and significantly lower rates of clinical worsening compared with remaining on .
Professor Marius Hoeper
presents the REPLACE study results
On behalf of the REPLACE investigators, Professor Marius Hoeper presents a summary of the findings of the REPLACE study.
Resources
Find resources associated with the study, including other riociguat publications